The dismissal of the auditor, already flagged with a going-concern opinion and known material weaknesses, is a strong distress signal. Watch for the new auditor's report on FY2026 financials—if KC also issues a going-concern qualification or uncovers additional deficiencies, equity risk escalates further. A capital raise or restructuring announcement in the near term is plausible.
Price Chart
Executive Summary
ABVC BioPharma dismissed auditor Simon & Edward, LLP (S&E) and engaged Kreit & Chiu CPA LLP (KC) as its new independent registered public accounting firm on June 30, 2026. The prior auditor's reports for FY2024 and FY2025 included a going-concern explanatory paragraph, and the company had pre-existing material weaknesses in internal control over financial reporting. No disagreements or reportable events (other than the known material weaknesses) occurred with S&E, per the filing.
Key Facts
- S&E was dismissed as auditor effective June 30, 2026, and KC was engaged for FY2026.
- S&E's reports for FY2024 and FY2025 contained a going-concern explanatory paragraph.
- The company had previously disclosed material weaknesses in internal control over financial reporting.
- No accounting disagreements or reportable events (other than the material weaknesses) occurred with S&E during the past two fiscal years or the interim period.
Financial Impact
Auditor change on a $46M market cap company already carrying a going-concern opinion—elevates distress risk significantly.
Risk Factors
- Auditor change signals potential accounting or reporting complications that the new firm may highlight.
- Existing going-concern opinion and material weaknesses create heightened delisting or financing risk.
- Small market cap ($46M) and low analyst bullish sentiment (0%) amplify downside from any negative disclosure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-074949 |
| Document: ea029672301ex16-1.htm | 0001213900-26-074949 |
| Document: 0001213900-26-074949-index-headers.html | 0001213900-26-074949 |
| Document: 0001213900-26-074949-index.html | 0001213900-26-074949 |
| Document: 0001213900-26-074949.txt | 0001213900-26-074949 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 27d ago | DEF 14A | $1.04 $0.9700 | ▲ +6.73% | ▲ +8.68% | $1.05 (−0.96%) |
Aug 3, 2026 11w ago | 8-K | $1.07 $0.9850 | ▼ −7.94% | ▼ −7.84% | $1.05 (−1.87%) |
Jul 2, 2026 16w ago | 8-K | $1.80 $1.45 | ▲ +19.44% | ▲ +20.37% | $1.05 (+41.67%) |
Mar 3, 2026 33w ago | 8-K | $1.45 $1.42 | ▲ +2.07% | ▲ +0.74% | $1.05 (+27.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers